CAPTRUST Financial Advisors’s Taysha Gene Therapies TSHA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$91.6K	Buy	+13,455	New	+$79.6K	﹤0.01%	3051
2026 Q1	–	Sell	-15,113	Closed	-$83.1K	–	3124
2025 Q4	$83.1K	Buy	+15,113	New	+$73.4K	﹤0.01%	2629
2022 Q3	–	Sell	-821	Closed	-$3K	–	3909
2022 Q2	$3K	Sell	821 -200	-20%	-$793	﹤0.01%	4346
2022 Q1	$7K	Hold	1,021	–	–	﹤0.01%	3999
2021 Q4	$12K	Hold	1,021	–	–	﹤0.01%	3624
2021 Q3	$19K	Hold	1,021	–	–	﹤0.01%	3206
2021 Q2	$22K	Buy	1,021 +60	+6%	+$1.38K	﹤0.01%	3048
2021 Q1	$20K	Buy	961 +241	+33%	+$6.53K	﹤0.01%	3007
2020 Q4	$19K	Buy	720 +350	+95%	+$7.54K	﹤0.01%	2283
2020 Q3	$8K	Buy	+370	New	+$8.7K	﹤0.01%	2383

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAPTRUST Financial Advisors's TSHA Position: Q2 2026 in Review

CAPTRUST Financial Advisors opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 13,455 shares worth $91.6K. The stake represents ﹤0.01% of the portfolio and ranks #3051 among its holdings. This is a return to the name: CAPTRUST Financial Advisors previously reported a position in TSHA as recently as Q4 2025.

CAPTRUST Financial Advisors first reported a position in TSHA in Q3 2020 and has held it in 10 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

CAPTRUST Financial Advisors held 13,455 shares of Taysha Gene Therapies worth $91.6K as of Q2 2026.
Taysha Gene Therapies was a new CAPTRUST Financial Advisors position in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3051 holding.
CAPTRUST Financial Advisors first reported a position in Taysha Gene Therapies in Q3 2020 and has held it in 10 quarters since.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.